SCHEMBL26605437

SCHEMBL26605437

[CH2]NC(=O)c1cn(C)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
KDM5A P29375 1/20 0.40
SMYD3 Q9H7B4 2/20 0.38
KCNA3 P22001 1/20 0.36
NTRK1 P04629 1/20 0.36
GRM2 Q14416 2/20 0.34
RBP4 P02753 1/20 0.34
ACKR3 P25106 1/20 0.33
CDK9 P50750 1/20 0.33
CSNK1D P48730 1/20 0.33
CSNK1E P49674 1/20 0.33
XIAP P98170 1/20 0.33
BIRC2 Q13490 1/20 0.33
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
TSHR P16473 1/20 0.32
MTOR P42345 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662858 0.82 BAZ2B (0.46) GSK3BDYRK1AKDM5ASMYD3KCNA3
SCHEMBL12911102 0.81 P2RX7 (0.42) GSK3BDYRK1AKDM5ASMYD3KCNA3
SCHEMBL17518681 0.81 GSK3B (0.42) GSK3BDYRK1AKDM5ASMYD3KCNA3
SCHEMBL2757975 0.78 CNR1 (0.40) GSK3BDYRK1AKDM5ASMYD3GRM2
SCHEMBL3266560 0.78 GRM2 (0.42) GSK3BDYRK1AKDM5ASMYD3KCNA3
SCHEMBL12443623 0.78 CNR1 (0.40) GSK3BDYRK1AKDM5ASMYD3NTRK1
SCHEMBL9726872 0.78
SCHEMBL24253400 0.77 KCNA3 (0.41) GSK3BDYRK1AKDM5ASMYD3KCNA3
SCHEMBL1614140 0.75
SCHEMBL170374 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348516-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-11-02 US claimed
EP-4269400-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS Molecure SA (PL) 2023-11-01 EP claimed
US-20230348516-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-11-02 US disclosed
EP-4269400-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS Molecure SA (PL) 2023-11-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348516-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA GSK3B 1127/4885DYRK1A 718/4885KDM5A 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.